Chronic pyelonephritis
- Overview
- Theory
- Diagnosis
- Management
- Follow up
- Resources
Treatment algorithm
Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups: see disclaimer
all patients
treatment of underlying cause
No specific treatment of chronic pyelonephritis is possible; however, patients should have underlying causes (e.g., infection, obstruction) treated appropriately to prevent further damage. In both children and adults, recurrent infections resulting from anatomic abnormalities are a major factor in the development of chronic pyelonephritis and renal failure. In chronic interstitial nephritis, the primary etiologic factors are vesicoureteral reflux and obstruction.[11]Riccabona M, Fotter R. Urinary tract infection in infants and children: an update with special regard to the changing role of reflux. Eur Radiol. 2004 Mar;14 Suppl 4:L78-88. http://www.ncbi.nlm.nih.gov/pubmed/14752568?tool=bestpractice.com
nephrectomy and antibiotics
Treatment recommended for ALL patients in selected patient group
Urgent urologic consultation is essential in the management of these patients.
The main treatment of this chronic destructive inflammatory process is surgical.
Medical treatment does not cure this disease, but because most patients are diabetic, good glucose control and treatment of infection with gram-negative cover are recommended. Antibiotic treatment includes third-generation cephalosporins, fluoroquinolones, extended-spectrum penicillins, aminoglycosides, and carbapenem antibiotics.
In the setting of increasing drug resistance in uropathogens, the following newer antibiotics are approved in some countries for use in adults with complicated urinary tract infection (UTI) caused by susceptible organisms who have limited or no alternative options: meropenem/vaborbactam, plazomicin, cefiderocol, and imipenem/cilastatin/relebactam.[46]Dhillon S. Meropenem/vaborbactam: a review in complicated urinary tract infections. Drugs. 2018 Aug;78(12):1259-70. https://link.springer.com/article/10.1007%2Fs40265-018-0966-7 http://www.ncbi.nlm.nih.gov/pubmed/30128699?tool=bestpractice.com [47]Wagenlehner FME, Cloutier DJ, Komirenko AS, et al. Once-daily plazomicin for complicated urinary tract infections. N Engl J Med. 2019 Feb 21;380(8):729-40. https://www.nejm.org/doi/10.1056/NEJMoa1801467 http://www.ncbi.nlm.nih.gov/pubmed/30786187?tool=bestpractice.com [48]Tamma PD, Heil EL, Justo JA, et al. Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections. Clin Infect Dis. 2024 Aug 7:ciae403. https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciae403/7728556 http://www.ncbi.nlm.nih.gov/pubmed/39108079?tool=bestpractice.com
Because of the destructive nature of the lesions, xanthogranulomatous pyelonephritis (XGP) may be mistaken for renal cell carcinoma on radiologic images (e.g., CT scan). The correct diagnosis may not be made until the patient undergoes surgery.
The treatment of this rare infectious disease is surgical; this generally includes partial or, typically, total nephrectomy.[16]Grainger RG, Longstaff AJ, Parsons MA. Xanthogranulomatous pyelonephritis: a reappraisal. Lancet. 1982 Jun 19;1(8286):1398-401. http://www.ncbi.nlm.nih.gov/pubmed/6123688?tool=bestpractice.com [25]Alan C, Atas S, Tunc B. Xanthogranulomatous pyelonephritis with psoas abscess: 2 cases and review of the literature. Int Urol Nephrol. 2004;36(4):489-93. http://www.ncbi.nlm.nih.gov/pubmed/15787322?tool=bestpractice.com The disease rarely involves both kidneys and has not been shown to progress serially from one kidney to the other, and surgical resection is curative.[16]Grainger RG, Longstaff AJ, Parsons MA. Xanthogranulomatous pyelonephritis: a reappraisal. Lancet. 1982 Jun 19;1(8286):1398-401. http://www.ncbi.nlm.nih.gov/pubmed/6123688?tool=bestpractice.com
Treatment course: 10-14 days. A repeat urine culture should be performed at least 48 hours after the last antibiotic dose in order to document resolution of the UTI.
Primary options
ceftriaxone: 1 g intravenously every 24 hours
OR
ciprofloxacin: 200-400 mg intravenously every 12 hours
OR
gentamicin: 3-5 mg/kg/day intravenously
OR
ampicillin/sulbactam: 3 g intravenously every 6 hours
More ampicillin/sulbactamDose consists of 2 g of ampicillin plus 1 g of sulbactam.
OR
piperacillin/tazobactam: 3.375 g intravenously every 6-8 hours
More piperacillin/tazobactamDose consists of 3 g of piperacillin plus 0.375 g of tazobactam.
OR
imipenem/cilastatin: 250-500 mg intravenously every 6-8 hours
More imipenem/cilastatinDose refers to imipenem component.
OR
ertapenem: 1 g intravenously every 24 hours
OR
ceftazidime/avibactam: 2.5 g intravenously every 8 hours
More ceftazidime/avibactamDose consists of 2 g of ceftazidime plus 0.5 g of avibactam.
Secondary options
meropenem/vaborbactam: 4 g intravenously every 8 hours
More meropenem/vaborbactamDose consists of 2 g of meropenem plus 2 g of vaborbactam.
OR
plazomicin: 15 mg/kg intravenously every 24 hours
OR
cefiderocol: 2 g intravenously every 8 hours
OR
imipenem/cilastatin/relebactam: 1.25 g intravenously every 6 hours
More imipenem/cilastatin/relebactamDose consists of 500 mg of imipenem plus 500 mg of cilastatin plus 250 mg of relebactam.
percutaneous drainage, antibiotics, and supportive therapy
Treatment recommended for ALL patients in selected patient group
Urgent urologic consultation is essential in the management of these patients.
If patients are hemodynamically stable, percutaneous drainage or stent placement to relieve obstruction may be the preferred option, together with antibiotics.[17]Mokabberi R, Ravakhah K. Emphysematous urinary tract infections: diagnosis, treatment and survival (case review series). Am J Med Sci. 2007 Feb;333(2):111-6. http://www.ncbi.nlm.nih.gov/pubmed/17301591?tool=bestpractice.com [18]Rubenstein JN, Schaeffer AJ. Managing complicated urinary tract infections: the urologic view. Infect Dis Clin North Am. 2003 Jun;17(2):333-51. http://www.ncbi.nlm.nih.gov/pubmed/12848473?tool=bestpractice.com [51]Somani BK, Nabi G, Thorpe P, et al; ABACUS Research Group. Is percutaneous drainage the new gold standard in the management of emphysematous pyelonephritis? Evidence from a systematic review. J Urol. 2008 May;179(5):1844-9. http://www.ncbi.nlm.nih.gov/pubmed/18353396?tool=bestpractice.com If no clinical improvement is noted within 24 to 48 hours, a repeat CT scan should be obtained, and nephrectomy considered.[1]Huang JJ, Tseng CC. Emphysematous pyelonephritis: clinicoradiological classification, management, prognosis, and pathogenesis. Arch Intern Med. 2000 Mar 27;160(6):797-805. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/485260 http://www.ncbi.nlm.nih.gov/pubmed/10737279?tool=bestpractice.com
Most patients are acutely ill, and stabilization in the emergency department with adequate fluid resuscitation and tissue oxygenation has been shown to decrease morbidity and improve mortality.[26]Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001 Nov 8;345(19):1368-77. https://www.nejm.org/doi/full/10.1056/NEJMoa010307 http://www.ncbi.nlm.nih.gov/pubmed/11794169?tool=bestpractice.com
Intravenous antibiotics are given for this severe infection; duration of treatment depends on clinical response to therapy. Antibiotic treatment includes third-generation cephalosporins, fluoroquinolones, extended-spectrum penicillins, aminoglycosides, and carbapenem antibiotics.
In the setting of increasing drug resistance in uropathogens, the following newer antibiotics are approved in some countries for use in adults with complicated urinary tract infection (UTI) caused by susceptible organisms who have limited or no alternative options: meropenem/vaborbactam, plazomicin, cefiderocol, and imipenem/cilastatin/relebactam.[46]Dhillon S. Meropenem/vaborbactam: a review in complicated urinary tract infections. Drugs. 2018 Aug;78(12):1259-70. https://link.springer.com/article/10.1007%2Fs40265-018-0966-7 http://www.ncbi.nlm.nih.gov/pubmed/30128699?tool=bestpractice.com [47]Wagenlehner FME, Cloutier DJ, Komirenko AS, et al. Once-daily plazomicin for complicated urinary tract infections. N Engl J Med. 2019 Feb 21;380(8):729-40. https://www.nejm.org/doi/10.1056/NEJMoa1801467 http://www.ncbi.nlm.nih.gov/pubmed/30786187?tool=bestpractice.com [48]Tamma PD, Heil EL, Justo JA, et al. Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections. Clin Infect Dis. 2024 Aug 7:ciae403. https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciae403/7728556 http://www.ncbi.nlm.nih.gov/pubmed/39108079?tool=bestpractice.com
Treatment course: 10-14 days. A repeat urine culture should be performed at least 48 hours after the last antibiotic dose in order to document resolution of the UTI.
Primary options
ceftriaxone: 1 g intravenously every 24 hours
OR
ciprofloxacin: 200-400 mg intravenously every 12 hours
OR
gentamicin: 3-5 mg/kg/day intravenously
OR
ampicillin/sulbactam: 3 g intravenously every 6 hours
More ampicillin/sulbactamDose consists of 2 g of ampicillin plus 1 g of sulbactam.
OR
piperacillin/tazobactam: 3.375 g intravenously every 6-8 hours
More piperacillin/tazobactamDose consists of 3 g of piperacillin plus 0.375 g of tazobactam.
OR
imipenem/cilastatin: 250-500 mg intravenously every 6-8 hours
More imipenem/cilastatinDose refers to imipenem component.
OR
ertapenem: 1 g intravenously every 24 hours
OR
ceftazidime/avibactam: 2.5 g intravenously every 8 hours
More ceftazidime/avibactamDose consists of 2 g of ceftazidime plus 0.5 g of avibactam.
Secondary options
meropenem/vaborbactam: 4 g intravenously every 8 hours
More meropenem/vaborbactamDose consists of 2 g of meropenem plus 2 g of vaborbactam.
OR
plazomicin: 15 mg/kg intravenously every 24 hours
OR
cefiderocol: 2 g intravenously every 8 hours
OR
imipenem/cilastatin/relebactam: 1.25 g intravenously every 6 hours
More imipenem/cilastatin/relebactamDose consists of 500 mg of imipenem plus 500 mg of cilastatin plus 250 mg of relebactam.
nephrectomy
Treatment recommended for SOME patients in selected patient group
Urgent urologic consultation is essential in the management of these patients.
In the past, nephrectomy was recommended in all patients. However, patients who undergo emergency nephrectomy in the face of sepsis are significant surgical risks.
Patients who have no clinical improvement with drainage and antibiotics within 24 to 48 hours, or who are severely ill or septic, need nephrectomy.[1]Huang JJ, Tseng CC. Emphysematous pyelonephritis: clinicoradiological classification, management, prognosis, and pathogenesis. Arch Intern Med. 2000 Mar 27;160(6):797-805. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/485260 http://www.ncbi.nlm.nih.gov/pubmed/10737279?tool=bestpractice.com [53]Soo Park B, Lee SJ, Wha Kim Y, et al. Outcome of nephrectomy and kidney-preserving procedures for the treatment of emphysematous pyelonephritis. Scand J Urol Nephrol. 2006;40(4):332-8. http://www.ncbi.nlm.nih.gov/pubmed/16916776?tool=bestpractice.com
Operative treatment, such as nephrectomy and drainage, along with antibiotics has been shown to decrease the mortality rate.[53]Soo Park B, Lee SJ, Wha Kim Y, et al. Outcome of nephrectomy and kidney-preserving procedures for the treatment of emphysematous pyelonephritis. Scand J Urol Nephrol. 2006;40(4):332-8. http://www.ncbi.nlm.nih.gov/pubmed/16916776?tool=bestpractice.com
Choose a patient group to see our recommendations
Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups. See disclaimer
Use of this content is subject to our disclaimer